Actinogen Medical (ACW) 2021年年度报告「ASX」.pdf

1、Annual Report 2021ContentsWho we are 1Highlights 2The Xanamem Pipeline 3About Xanamem and Cortisol Diseases 4Chairmans Letter 7Chief Executive Officers Letter 8Corporate Strategy 10Operating&Financial Review 12Board of Directors and Company Secretary 17Executive Leadership Team 19Directors Report 20

2、Remuneration Report 22Auditors Independence Declaration 39Financial Report 40Directors Declaration 66Independent Auditors Report 67Corporate Governance Statement 72Shareholder Information 82Corporate Directory 84AGM detailsActinogen Medical LimitedABN:14 086 778 476Annual General MeetingDue to healt

3、h and safety priorities,community expectations and COVID-19 restrictions on public gatherings,this years Annual General Meeting will be a virtual meeting.Date:10 November 2021 Meeting time and details to be advised.Actinogen is a neurotherapeutics developer realising a revolutionary therapy so neuro

4、logy patients can live their best livesAnnual Financial Report1HighlightsReceived Rare Paediatric Disease Designation(RPDD)for Xanamem in Fragile X Syndrome from US FDASecured new capital exceeding$10 million to fund planned clinical trialsAppointed highly credentialled CEO Dr Steven GourlayStrength

5、ened intellectual property portfolio via two patent applications filed for Xanamem to extend patent life protection until 2040Appointed Corden Pharma as scale-up manufacturerAppointed key consultants to drive strategic projectsCommenced the XanaMIA Phase 2 study for Alzheimers DiseaseActinogens FY21

6、 achievements have set strong foundations for the companys future success Received positive XanaFX Phase 2 trial design feedback from US FDA for Fragile X SyndromeDemonstrated high levels of target occupancy in the brain for Xanamem daily doses ranging from 5mg to 30mgActinogen Medical Limited2Mild